REGN vs TIL · P/E 14, rev $14.34B vs $51.3M cap
Regeneron Pharmaceuticals Inc (REGN) versus Instil Bio Inc. (TIL) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Instil Bio Inc. (TIL) is a biotechnology company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
TIL does not have a complete income-statement cache yet.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. TIL currently screens at market cap $51.3M.
Not investment advice. Open the REGN and TIL stock pages for the full models.
Not investment advice.